Potential novel therapies for chronic obstructive pulmonary disease

Novartis Foundation Symposium

Volumn 234, Issue , 2001, Pages 255-272

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ADMINISTRATION ROUTE; HUMAN; IMMUNOLOGY; LUNG ALVEOLUS; REVIEW;

DRUG ADMINISTRATION ROUTES; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PROTEASE INHIBITORS; PULMONARY ALVEOLI;

EID: 0035219395     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (33)

1. Barnes PJ 1998a Chronic obstructive pulmonary disease: new opportunities for drug development. Trends Pharmacol Sci 19:415-423
2. Barnes PJ 1998b New therapies for chronic obstructive pulmonary disease. Thorax 53:137-147
3. Barnes PJ 1999 Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax 54:245-252
4. Barnes PJ, Karin M 1997 Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 336:1066-1071
5. Barnes PJ, Chung KF, Page CP 1998 Inflammatory mediators of asthma: an update. Pharmacol Rev 50:515-596
6. Carter AB, Monick MM, Hunninghake GW 1999 Both erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 20:751-758
7. Cawston T 2001 Matrix metalloproteinases and inhibitors. In: Chronic obstructive pulmonary disease: pathogenesis to treatment. Wiley, Chichester (Novartis Found Symp 234) p 205-228
8. Culpitt SV, Nightingale JA, Barnes PJ 1999 Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1635-1639
9. Di Stefano A, Maestrelli P, Roggeri A et al 1994 Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 149:803-810
10. Disse B, Speck GA, Rominger KL, Witek TJ JR, Hammer R 1999 Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64:457-464
11. 4 antagonist LY293111 on allergen-induced responses in asthma. Thorax 51:1178-1184
12. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958
13. Hill AT, Bayley D, Stockley RA 1999 The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 160:893-898
14. Keatings VM, Collins PD, Scott DM, Barnes PJ 1996 Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153:530-534
15. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ 1997 Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542-548
16. Kogan TP, Dupré B, Bui H et al 1998 Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane (TBC1269). J Med Chem 41:1099-1111
17. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM 1995 IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96:2304-2310
18. Lee JC, Kassis S, Kumar S, Badger A, Adams JL 1999 p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 82:389-397
19. Luster AD 1998 Chemokines - chemotactic cytokines that mediate inflammation. New Engl J Med 338:436-445
20. MacNee W 2001 Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. In: Chronic obstructive pulmonary disease: pathogenesis to treatment. Wiley, Chichester (Novartis Found Symp 234) p 169-188
21. Massaro D 2001 Alveolus formation: critical period, plasticity and retinoid regulation. In: Chronic obstructive pulmonary disease: pathogenesis to treatment. Wiley, Chichester (Novartis Found Symp 234) p 229-243
22. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R 1999 Differential IKK activation and IκBa degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem 274:19965-19972
23. Nielson CP, Vestal RE, Sturm RJ, Heaslip R 1990 Effect of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86:801-808
24. Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T 1998 Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 125:1315-1324
25. Pauwels RA, Lofdahl CG, Laitinen LA et al 1999 Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340:1548-1553
26. Ramnarine SI, Liu YC, Rogers DF 1998 Neuroregulation of mucus secretion by opioid receptors and K(ATP) and BK(Ca) channels in ferret trachea in vitro. Br J Pharmacol 123:1631-1638
27. Silverman E 2001 Genetics of chronic obstructive pulmonary disease. In: Chronic obstructive pulmonary disease: pathogenesis to treatment. Wiley, Chichester (Novartis Found Symp 234) p 45-65
28. Stockley RA 2001 Proteases and antiproteases. In: Chronic obstructive pulmonary disease: pathogenesis to treatment. Wiley, Chichester (Novartis Found Symp 234) p 189-204
29. Torphy TJ, Barnette MS, Underwood DC et al 1999 Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12:131-136
30. van Deventer SJ, Elson CO, Fedorak RN 1997 Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113:383-389
31. Vestbo J, Prescott E, Lange P 1996 Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 153:1530-1535
32. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM 1999 Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56:170-174
33. White JR, Lee JM, Young PR et al 1998 Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098